Biotech news for Wednesday, June 24, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Armata Pharmaceuticals ( ARMP ) traded higher on Tuesday after the Department of Defense provided the company with $2.5M in additional funding to help advance its lead program, an antibacterial agent identified as AP-SA02. The funding relates to an agreement t…
Galectin Therapeutics ( GALT ) announced on Tuesday it has reached an agreement with the FDA regarding a Phase 3 program to test its lead asset belapectin in cirrhosis and portal hypertension linked to the liver disease metabolic dysfunction-associated steatoh…
Boundless Bio ( BOLD ) shares surge over 95% premarket after the company and and Serapha Bio entered into a definitive all-stock merger agreement . Following the transaction, the combined company will operate as Serapha Bio and is expected to trade on Nasdaq u…
AbbVie ( ABBV ) and Enanta Pharmaceuticals ( ENTA ) announced on Tuesday that the European Commission has approved a label expansion for their jointly developed hepatitis C therapy, Maviret. Accordingly, the once-daily tablet, previously available in the regio…
AscentXmedia/E+ via Getty Images Sangamo Therapeutics ( SGMO ) on Tuesday reported that it has commenced voluntary Chapter 11 bankruptcy proceedings in Delaware to facilitate a court-supervised reorganization, concurrent with entering into separate asset sale…
AbbVie ( ABBV ) Tuesday said that the European Commission has approved Skyrizi (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy. Approval wa…
adrian825 Sanofi ( SNY ) is providing MacroGenics ( MGNX ) a $24.5M milestone payment following the recently approved additional indication of Tzield (teplizumab) to delay the decline in endogenous insulin production in children ages 8-17 years recently diagno…
Wall Street finished Monday’s session in mixed fashion as renewed uncertainty around weekend U.S.–Iran peace negotiations pressured sentiment, while weakness in major technology names added to downside momentum in growth stocks. The S&P 500 ( SP500 ) ended…
MoonLake Immunotherapeutics ( MLTX ) proposed a public offering of $150M of Class A ordinary shares and, for certain investors, pre-funded warrants. The company expects to grant underwriters a 30-day option to purchase up to an additional $22.5M of Class A ord…
uniQure ( QURE ) announced on Monday that it has commenced a $150M underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. Shares of QURE slipped nearly 3% d…
Moderna ( MRNA ) snapped a six-session winning streak on Monday, with shares closing down 7.13% at $59.40. Despite the decline, the stock has been one of the market's standout performers recently. Over the previous six sessions, Moderna surged more than 39%, s…
Achieve Life Sciences ( ACHV ) is up ~10% in Monday morning trading despite receiving a Complete Response Letter from the US FDA for cytisinicline, its smoking cessation asset. The company said the agency highlighted remaining manufacturing-related issues rela…
Exelixis ( EXEL ) shares are down in Monday morning trading after the biotech announced that a final analysis of one of the phase 3 dual primary endpoints for zanzalintinib for metastatic colorectal cancer didn't meet statistical significance. The STELLAR-303…
sasirin pamai/iStock via Getty Images While there are already several drugs approved to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis, Shalabh Gupta isn't fazed. As CEO of Unicycive Therapeutics ( UNCY ), Gupta, an MD by tra…
musmus culus/iStock via Getty Images The US FDA has awarded Praxis Precision Medicines ( PRAX ) Breakthrough Therapy Designation for elsunersen for seizures associated with SCN2A developmental and epileptic encephalopathy. The asset already has Breakthrough Th…
AbbVie ( ABBV ) has agreed to acquire Apogee Therapeutics ( APGE ) in an all-cash deal valued at $135.11 per share, adding Apogee’s portfolio of clinical-stage treatments for inflammatory and immunological diseases to its pipeline. The transaction values Apoge…
skynesher/E+ via Getty Images Regenxbio ( RGNX ) shares rose as much as 37% in premarket trading on Monday after the Wall Street Journal reported that the FDA has agreed to reverse the rejection of the firm’s rare-disease drug. Regenxbio plans to refile its ap…